View Financial HealthPanacea Life Sciences Holdings 배당 및 자사주 매입배당 기준 점검 0/6Panacea Life Sciences Holdings 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jul 16Panacea Life Sciences Holdings, Inc. Files Form 15Panacea Life Sciences Holdings, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share.공시 • Jun 13Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: $0.05 to $0.2 Discount Per Security: $0공시 • Oct 07Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023. Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc. on October 5, 2023.공시 • Aug 17Panacea Life Sciences Holdings, Inc. announced delayed 10-Q filingOn 08/15/2023, Panacea Life Sciences Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 03Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million on August 2, 2023. The consideration includes $2 million in cash, $3 million worth of Panacea Stock and additional earn-out components consisting of $15 million of Panacea Stock. The transaction is subject to Panacea’s satisfactory completion of due diligence of SSH and Halucenex, receipt of applicable corporate approvals of the transaction by the board of directors and shareholders, the execution of the definitive agreement and any ancillary agreements, the receipt of any regulatory approvals and third-party consents, financing (debt or equity) arrangements for Panacea’s $2 million cash payment and projected cash flow deficits from the transaction, on terms satisfactory to Panacea, certain key management personnel and employees entering into consultancy and restrictive covenant agreements with Panacea on terms agreed to with Panacea, confirmation that SSH and Halucenex own their respective intellectual property or licenses and have all required approval for all business operations and ownership including legal and regulatory approvals, by all regulatory agencies, there being no material adverse change in the business, results of operations, prospects, condition (financial or otherwise) or assets of SSH and Halucenex. Paradox Capital Partners, LLC acted as advisor to Panacea.공시 • Jul 12Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp on July 3, 2023. The purchase price for the acquisition consists of no cash and the agreement to issue approximately 85,000 shares of a new class of convertible preferred stock, which is convertible into approximately 8.5 million shares of common stock to Nitro Kava & Kratom. The acquisition includes eight retail locations in the Tampa, Florida area, offering Kava, Kratom, VAPE and CBD products and beverages operating as Nitro Kava & Kratom, including inventory, equipment and recipes, distribution facilities and a warehouse located in Largo, Florida. Nitro Kava & Kratom generated $2.9 million of annual revenues (unaudited) for the fiscal year ended December 31, 2022. Closing of the acquisition is subject to satisfaction of customary terms and conditions for a transaction of this kind, including delivery by sellers of audited financial statements for the prior two completed fiscal years for the acquisition. The transaction is subject to N7 Enterprises shareholders.공시 • Jan 24Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023.공시 • Jul 24Panacea Life Sciences Holdings, Inc. Announces Resignation of Janice Nerger to Its Board of DirectorsPanacea Life Sciences Holdings, Inc. announced that on July 21, 2022, Dr. Janice Nerger resigned as a member of the Board of Directors, effective immediately. Dr. Nerger has accepted the position of interim provost at Colorado State University and has decided to focus on her new position.공시 • Jul 15Panacea Life Sciences Announces Launch of CBDA Oil Drops as Potential Complementary Treatment for Long COVIDPanacea Life Sciences Holdings, Inc. announced the addition of CBDA Oil Drops, which is thought to provide potential advantages as a preventative agent against SARS-CoV-2 as well as the effects of Long COVID. In January 2022, the results of a study led by Oregon State University researcher Richard van Breemen were published in the Journal of Natural Products and concluded that CBDA and CBGA can bind to the SARS-CoV-2 spike protein, blocking the virus's ability to infect people. Much more research is necessary to make definitive claims, but as a compliment to vaccines, CBD and CBDA may provide effective prevention and treatment of SARS-CoV-2. Panacea's CBDA Oil Drops tincture, which contains 50mg of CBDA per serving as well as immunity boosting Zinc and Vitamin D, remains one of few products of its kind to be available on the market.공시 • Aug 18Exactus, Inc. announced delayed 10-Q filingOn 08/17/2021, Exactus, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 PLSH 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: PLSH 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Panacea Life Sciences Holdings 배당 수익률 vs 시장PLSH의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PLSH)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.1%업계 평균 (Pharmaceuticals)1.9%분석가 예측 (PLSH) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PLSH 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PLSH 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PLSH 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: PLSH 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/06 12:58종가2026/07/02 00:00수익2024/03/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Panacea Life Sciences Holdings, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jul 16Panacea Life Sciences Holdings, Inc. Files Form 15Panacea Life Sciences Holdings, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share.
공시 • Jun 13Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: $0.05 to $0.2 Discount Per Security: $0
공시 • Oct 07Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023. Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc. on October 5, 2023.
공시 • Aug 17Panacea Life Sciences Holdings, Inc. announced delayed 10-Q filingOn 08/15/2023, Panacea Life Sciences Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 03Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million on August 2, 2023. The consideration includes $2 million in cash, $3 million worth of Panacea Stock and additional earn-out components consisting of $15 million of Panacea Stock. The transaction is subject to Panacea’s satisfactory completion of due diligence of SSH and Halucenex, receipt of applicable corporate approvals of the transaction by the board of directors and shareholders, the execution of the definitive agreement and any ancillary agreements, the receipt of any regulatory approvals and third-party consents, financing (debt or equity) arrangements for Panacea’s $2 million cash payment and projected cash flow deficits from the transaction, on terms satisfactory to Panacea, certain key management personnel and employees entering into consultancy and restrictive covenant agreements with Panacea on terms agreed to with Panacea, confirmation that SSH and Halucenex own their respective intellectual property or licenses and have all required approval for all business operations and ownership including legal and regulatory approvals, by all regulatory agencies, there being no material adverse change in the business, results of operations, prospects, condition (financial or otherwise) or assets of SSH and Halucenex. Paradox Capital Partners, LLC acted as advisor to Panacea.
공시 • Jul 12Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp on July 3, 2023. The purchase price for the acquisition consists of no cash and the agreement to issue approximately 85,000 shares of a new class of convertible preferred stock, which is convertible into approximately 8.5 million shares of common stock to Nitro Kava & Kratom. The acquisition includes eight retail locations in the Tampa, Florida area, offering Kava, Kratom, VAPE and CBD products and beverages operating as Nitro Kava & Kratom, including inventory, equipment and recipes, distribution facilities and a warehouse located in Largo, Florida. Nitro Kava & Kratom generated $2.9 million of annual revenues (unaudited) for the fiscal year ended December 31, 2022. Closing of the acquisition is subject to satisfaction of customary terms and conditions for a transaction of this kind, including delivery by sellers of audited financial statements for the prior two completed fiscal years for the acquisition. The transaction is subject to N7 Enterprises shareholders.
공시 • Jan 24Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023.
공시 • Jul 24Panacea Life Sciences Holdings, Inc. Announces Resignation of Janice Nerger to Its Board of DirectorsPanacea Life Sciences Holdings, Inc. announced that on July 21, 2022, Dr. Janice Nerger resigned as a member of the Board of Directors, effective immediately. Dr. Nerger has accepted the position of interim provost at Colorado State University and has decided to focus on her new position.
공시 • Jul 15Panacea Life Sciences Announces Launch of CBDA Oil Drops as Potential Complementary Treatment for Long COVIDPanacea Life Sciences Holdings, Inc. announced the addition of CBDA Oil Drops, which is thought to provide potential advantages as a preventative agent against SARS-CoV-2 as well as the effects of Long COVID. In January 2022, the results of a study led by Oregon State University researcher Richard van Breemen were published in the Journal of Natural Products and concluded that CBDA and CBGA can bind to the SARS-CoV-2 spike protein, blocking the virus's ability to infect people. Much more research is necessary to make definitive claims, but as a compliment to vaccines, CBD and CBDA may provide effective prevention and treatment of SARS-CoV-2. Panacea's CBDA Oil Drops tincture, which contains 50mg of CBDA per serving as well as immunity boosting Zinc and Vitamin D, remains one of few products of its kind to be available on the market.
공시 • Aug 18Exactus, Inc. announced delayed 10-Q filingOn 08/17/2021, Exactus, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.